The net benefit of GLP-1 receptor agonists in adults with overweight or obesity who do not have diabetes depends on their weight loss target and willingness to accept harms, according to researchers.
Although GLP-1 receptor agonists have demonstrated effectiveness in reducing weight loss and risks for other chronic diseases, questions remain over whether the benefits outweigh the harms of the drugs, “including their cost-effectiveness and economic impact,” Hannah Moll, a PhD candidate from the department of epidemiology at the University of Zurich in Switzerland, and colleagues,